Qutenza approved for postherpetic neuralgia (PHN)

The FDA has approved Qutenza (capsaicin patch, from NeurogesX) for the management of neuropathic pain due to postherpetic neuralgia (PHN). Qutenza delivers a synthetic form of capsaicin through a dermal delivery system. Clinical studies have shown Qutenza to reduce PHN pain for up to 12 weeks following a single one-hour application, applied by a physician or healthcare professional.

Qutenza patch is expected to be available in a capsaicin 8% strength in the first half of 2010.

For more information call (877) 900-NGSX or visit www.Qutenza.com.